Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study

Byungyoon Yun, Sang Hoon Ahn, Jin‐Ha Yoon, Beom Kyung Kim – 28 June 2022 – Many studies have elucidated the protective associations of statin use with liver cancer or mortality, but studies examining statin's effect on the risk of progression to liver cirrhosis considering medical/metabolic conditions or lifestyle factors are lacking. We aimed to assess statin's benefit independent of conventional risk factors.

AASLD Hepatitis Elimination Efforts

Approximately 71 million people worldwide are chronically infected with hepatitis C virus (HCV) making it one of the world’s most common infectious diseases and public health threats. The epidemic continues to grow, with 1.75 million new infections annually. In 2016, the World Health Assembly ─ the forum through which the World Health Organization (WHO) is governed by 194 member states─initiated a worldwide goal for HCV elimination, defined as a reduction in HCV related mortality by 65 percent and new incidences by 80 percent by 2030. According to WHO, only 12 countries are on track to meet this goal.

Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti‐VEGF/TKI and immunotherapy

Nguyen H. Tran, Sergio Muñoz, Scott Thompson, Christopher L. Hallemeier, Jordi Bruix – 27 June 2022 – Hepatocellular carcinoma remains a global health challenge affecting close to 1 million cases yearly. Liver transplantation provides the best long‐term outcomes for those meeting strict criteria. Efforts have been made to expand these criteria, whereas others have attempted downstaging approaches.

Growth hormone deficiency and NAFLD: An overlooked and underrecognized link

Iliana Doycheva, Dana Erickson, Kymberly D. Watt – 27 June 2022 – Growth hormone and its mediator insulin‐like growth factor‐1 exert their effect on different organs and control various physiologic metabolic processes. Adult growth hormone deficiency (AGHD) presents with one or more components of metabolic syndrome and can be associated with nonalcoholic fatty liver disease (NAFLD).

Subscribe to